This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06603571 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 367 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight |
| Interventions | LY3841136; Tirzepatide; Placebo |
| Start | Sep 20, 2024 |
| Primary completion | Jul 1, 2026 |
| Study completion | Sep 14, 2026 |
| Results posted | Not yet |
| Registry last updated | Sep 29, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 48 |
6 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
